| Thomas Hyland Schaumberg, MD | |
|
1111 Ne 99th Ave Ste 200, Portland, OR 97220-9442 | |
| (503) 963-3030 | |
| (503) 963-3140 |
| Full Name | Thomas Hyland Schaumberg |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 38 Years |
| Location | 1111 Ne 99th Ave Ste 200, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174516827 | NPI | - | NPPES |
| 8154197 | Medicaid | WA | |
| 066113 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD15332 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Portland Medical Center | Portland, OR | Hospital |
| Mid-columbia Medical Center | The dalles, OR | Hospital |
| Providence Willamette Falls Medical Center | Oregon city, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Clinic Pc | 2860390408 | 319 |
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003991845 PECOS PAC ID: 5395656284 Enrollment ID: O20031113000626 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Entity Name | Oregon Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265417174 PECOS PAC ID: 2860390408 Enrollment ID: O20031222000096 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366536963 PECOS PAC ID: 6103728753 Enrollment ID: O20040123000371 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053862714 PECOS PAC ID: 7315856010 Enrollment ID: O20040304001330 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Entity Name | Providence Health & Services - Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912282369 PECOS PAC ID: 5294901922 Enrollment ID: O20120319000430 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Hyland Schaumberg, MD 541 Ne 20th Ave Ste 225, Portland, OR 97232-2895 Ph: (503) 963-2801 | Thomas Hyland Schaumberg, MD 1111 Ne 99th Ave Ste 200, Portland, OR 97220-9442 Ph: (503) 963-3030 |
News Archive
African Americans with a common genetic variation are at increased risk for developing Alzheimer's disease, while European Americans with the same variation are not, according to a study led by researchers at Rush University Medical Center.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.
By proposing $1.65 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria "in his 2014 budget request to Congress, President Obama gave the world the next big shove it needs to control and end AIDS, tuberculosis, and malaria," Kolleen Bouchane, director of ACTION, writes in the Huffington Post's "The Big Push" blog.
When you think back on your childhood, chances are there's a rich montage of sights and sounds that comes to mind. But, imagine if you couldn't have heard the ding of the ice cream truck or the sound of a barking dog – how would that have impacted the experiences of your youth?
› Verified 9 days ago
Salona Shrestha, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |